RxDoctor Payments Data

Eric Sugihara, DO

Otolaryngology · Fullerton, CANPI 1154661015

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (43.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Cochlear Americas accounts for 60.9% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $4,252 and has fallen 94.9% since, to $215 in 2025.

$6,389in general payments, 2019–2025

Across 73 payments — averaging $87.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cochlear Americas$4K
  • Stryker$1K
  • Intersect ENT, Inc.$244
  • Regeneron Healthcare Solutions, Inc.$223
  • GSK$180
  • Acclarent, Inc$160
  • plus $538 from 13 others
$20,987in research payments, 2019–2025

Across 10 payments — averaging $2098.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Cochlear Americas$21K

What the payments were for

  • Consulting fees$2,70442%
  • Travel & lodging$93215%
  • Food & beverage$2,75343%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,389 in reported general payments places this provider in the 85th percentile of 1,021 otolaryngology providers in California.

See all otolaryngology providers in California

Medicare billing

Part B allowed, 2024
$143,439
Medicare patients
393
Services billed
1,496

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab12$42,884
Azelastine Hcl149$3,523
Dexamethasone Sodium Phosphate44$2,436
Ipratropium Bromide100$2,289
Prednisolone Acetate40$1,906
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth20$1,712
Pantoprazole Sodium195$1,473
Ofloxacin60$1,373
Fluticasone Propionate78$1,122
Tobramycin-DexamethasoneTobramycin/Dexamethasone11$962
Fluocinolone Acetonide Oil48$930
Cefdinir24$467
Neomycin-Polymyxin-HydrocortNeomycin/Polymyxin B/Hydrocort12$446
Clotrimazole17$366
Acetic Acid13$283

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Fullerton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →